Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.61 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8114904 | 1.00 | LTA4H (0.61) | LTA4HKCNA5NPC1RAB9AMEN1 | |
| SCHEMBL6946206 | 0.92 | KDM4E (0.65) | TMEM97SIGMAR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3886790 | 0.90 | KDM4E (0.59) | TMEM97SIGMAR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5635479 | 0.90 | NPC1 (0.55) | LTA4HKCNA5NPC1RAB9AMEN1 | |
| SCHEMBL19025236 | 0.83 | LTA4H (0.65) | LTA4HKCNA5RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL7400087 | 0.83 | LTA4H (0.65) | LTA4HKCNA5NPC1RAB9AMEN1 | |
| SCHEMBL10696776 | 0.83 | HRH3 (0.56) | KCNA5ALDH1A1HRH3 | |
| SCHEMBL255201 | 0.82 | LTA4H (0.86) | LTA4HMEN1KMT2AKDM4EALDH1A1 | |
| Oxalic Acid SCHEMBL10698242 | 0.81 | KCNA5 (0.60) | KCNA5MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL3951411 | 0.80 | LTA4H (0.83) | LTA4HKDM4EALDH1A1SMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397616-B1 | LSD1 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3397616-B1 | LSD1 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-10233152-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2019-03-19 | — | — | US | disclosed |
| US-10233152-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3397616-A1 | LSD1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| US-20180127369-A1 | LSD1 Inhibitors | Mirati Therapeutics, Inc. | 2018-05-10 | — | — | US | disclosed |
| US-20180127369-A1 | LSD1 Inhibitors | Mirati Therapeutics, Inc. | 2018-05-10 | — | — | US | disclosed |
| US-9809541-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809541-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2017-11-07 | — | — | US | disclosed |
| WO-2017116558-A1 | LSD1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-6642231-B2 | Antineoplastic agents, treatment for neuronal injury and degeneration | AVENTIS PHARMACEUTICALS INC. | 2003-11-04 | — | — | US | disclosed |
| EP-1056744-B1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMA INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTISUB II INC. | 2003-06-05 | — | — | US | disclosed |
| US-6479487-B1 | INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS | AVENTIS PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| US-5760035-A | PIPERIDINE COMPOUNDS SUBSTITUTED WITH AN AMINOALKYL GROUP AND AN ARYLOXYALKYL GROUP, ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, IMMUNOSUPPRESSANTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-06-02 | — | — | US | disclosed |
| EP-0720602-B1 | 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS | KNOLL AG (DE) | 1997-07-09 | — | — | EP | disclosed |
| EP-0720602-A1 | 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS | KNOLL AG (DE) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995008535-A1 | 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS | KNOLL AG (DE) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233152-B2 | LSD1 inhibitors | KDM1B, KDM1A, KDM3A | LTA4H 2847/4885KCNA5 2407/4885NPC1 1310/4885 |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | CDK6, CDK5, CDK2 | LTA4H 2750/4885KCNA5 4176/4885NPC1 4697/4885 |
| US-20180127369-A1 | LSD1 Inhibitors | KDM1B, KDM1A, KDM3A | LTA4H 2847/4885KCNA5 2407/4885NPC1 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.